August 2021 Top Biopharma Deal: RemeGen – Seagen HER2-targeted ADC, Disitamab Vedotin for Solid Tumors
August 2021 Top Biopharma Deal Upfront
RemeGen development and commercialization deal with Seagen for disitamab vedotin
Highlighted Deal Financial Comps
Date Announced:
August 9, 2021
Total Deal Value:
$2,600M
Upfront Cash:
$200M
Upfront Equity:
n/a
Option Payments:
n/a
Total Milestones:
$2,400M (Dev., Reg., and Sales)
Royalties:
Tiered, high single-digit to mid-teens
Cost & Profit Split:
n/a
Deal Synopsis
The Asset:
Phase II HER2-targeted ADC disitamab vedotin for the treatment of several solid tumor types including urothelial, gastric, and breast cancer.
Deal Structure:
Development and Commercial License
Partnership Features:
Development responsibility and costs split by territory.
Deal Details:
- RemeGen granted Seagen exclusive, worldwide rights, excluding parts of Asia, to co-develop and commercialize HER2-targeted ADC, disitamab vedotin for the treatment of several solid tumor types including urothelial, gastric, and breast cancer.
- RemeGen will retain development and commercialization rights in Asia excluding Japan and Singapore and will be responsible for all submissions specific to its territory.
- Seagen will lead global clinical development and RemeGen will fund and operate clinical trials attributable to its territory.
- RemeGen will receive $200M up front and is eligible for up to $2.4B in development, regulatory, and commercialization milestones, plus undisclosed tiered, high single-digit to mid-teens royalties.
Last Month:
Congrats to RemGen and Seagen for landing the DealForma August 2021 Top Biopharma Deal of the Month. The Deal of the Month for July 2021 was Arvinas and Pfizer’s PROTAC deal with $1B up front for ARV-471. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
20,378
Licensing Deals
17,730
Funding Rounds
4,034
M&A
31,012
Company Profiles
5,478
Other Deals
26,505
Drug Sales Figures
All of this by stage, disease indication, modality, target...
More Research by DealForma
Introducing: DealForma plus Tableau
We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...
Venture & IPO – Medtech – Q1 2023
The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...